Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DE8V1R
|
|||
| Drug Name |
ARO-HIF2
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 1 | [1] | |
| Company |
Arrowhead Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HIF2-alpha messenger RNA (EPAS1 mRNA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Pathways in cancer | |||
| Renal cell carcinoma | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | |||
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | ||||
| Transcriptional regulation of pluripotent stem cells | ||||
| WikiPathways | Transcriptional regulation of pluripotent stem cells | |||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | ||||
| Adipogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04169711) Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug name ARO-HIF2). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.